European Medicines Agency Receives Type II Variation Application from Johnson & Johnson for Tecvayli (teclistamab) in Combination with Subcutaneous Darzalex (daratumumab) for the Treatment of RRMM (https://www.myeloma.org/news-events/multiple-myeloma-news/tecvayli-darzalex-combo-EMA-application)